Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
  • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
  • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• • A—HUMAN NECESSITIES
  • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
  • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
  • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
  • A01N43/72—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms
  • A01N43/80—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms five-membered rings with one nitrogen atom and either one oxygen atom or one sulfur atom in positions 1,2
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
  • A61K31/42—Oxazoles
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
  • A61K9/0029—Parenteral nutrition; Parenteral nutrition compositions as drug carriers
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P33/00—Antiparasitic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P33/00—Antiparasitic agents
  • A61P33/10—Anthelmintics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P33/00—Antiparasitic agents
  • A61P33/14—Ectoparasiticides, e.g. scabicides

Definitions

• This invention relates to a method for protecting an animal from a parasitic pest and parasitic pest infestation.
• PCT Patent Publication WO 05/085216 discloses isoxazoline derivatives of Formula i as insecticides wherein, inter alia, each of A 1 , A 2 and A 3 are independently C or N; G is a benzene ring; W is O or S; and X is halogen or C 1 -C 6 haloalkyl.
• This invention pertains to a method for protecting animals from a parasitic invertebrate pest comprising orally or parenterally administering to the animal a pesticidally effective amount of a compound of Formula 1 (including all geometric and steroisomers), an N -oxide or a salt thereof wherein R 1 is halogen, C 1 -C 3 haloalkyl or C 1 -C 3 haloalkoxy; R 2 is H, halogen, C 1 -C 3 alkyl, C 1 -C 3 haloalkyl or cyano; R 3 is H, halogen, C 1 -C 3 haloalkyl or C 1 -C 3 haloalkoxy; R 4 is halogen, C 1 -C 3 alkyl, C 1 -C 3 haloalkyl or C 1 -C 3 haloalkoxy; R 5 is H, CH 3 , C 2 -C 4 alkylcarbonyl, C 2 -C 4 haloalky
• This invention also relates to such method wherein the parasitic invertebrate pest or its environment is contacted with a composition comprising a biologically effective amount of a compound of Formula 1, an N -oxide or a salt thereof, and at least one additional component selected from the group consisting of surfactants, solid diluents and liquid diluents, said composition optionally further comprising a biologically effective amount of at least one additional biologically active compound or agent.
• This invention further provides a method for treating, preventing, inhibiting and/or killing ecto- and/or endoparasites comprising administering to and/or on the animal a pesticidally effective amount of a compound of Formula 1, an N -oxide or a salt thereof, (e.g., as a composition described herein).
• This invention also relates to such method wherein a pesticidally effective amount of a compound of Formula 1, an N -oxide or a salt thereof, (e.g., as a composition described herein) is administered to the environment (e.g., a stall or blanket) in which an animal resides.
• compositions comprising, “comprising,” “includes,” “including,” “has,” “having,” “contains” or “containing,” or any other variation thereof, are intended to cover a non-exclusive inclusion.
• a composition, a mixture, process, method, article, or apparatus that comprises a list of elements is not necessarily limited to only those elements but may include other elements not expressly listed or inherent to such composition, mixture, process, method, article, or apparatus.
• “or” refers to an inclusive or and not to an exclusive or. For example, a condition A or B is satisfied by any one of the following: A is true (or present) and B is false (or not present), A is false (or not present) and B is true (or present), and both A and B are true (or present).
• the terms “pest”, “invertebrate pest” and “parasitic invertebrate pest” include arthropods, gastropods and nematodes of economic importance as pests.
• arthropod includes insects, mites, spiders, scorpions, centipedes, millipedes, pill bugs and symphylans.
• gastropod includes snails, slugs and other Stylommatophora.
• nematode includes all of the helminths, such as roundworms, heartworms, and phytophagous nematodes (Nematoda), flukes (Tematoda), Acanthocephala, and tapeworms (Cestoda).
• invertebrate pest control means inhibition of invertebrate pest development (including mortality, feeding reduction, and/or mating disruption), and related expressions are defined analogously.
• the terms “pesticidal” and “pesticidally” refer to observable effects on a pest to provide protection of an animal from the pest. Pesticidal effects typically relate to diminishing the occurrence or activity of the target parasitic invertebrate pest. Such effects on the pest include necrosis, death, retarded growth, diminished mobility or lessened ability to remain on or in the host animal, reduced feeding and inhibition of reproduction. These effects on parasitic invertebrate pests provide control (including prevention, reduction or elimination) of parasitic infestation or infection of the animal.
• a parasite "infestation” refers to the presence of parasites in numbers that pose a risk to humans or animals.
• the infestation can be in the environment (e.g., in human or animal housing, bedding, and surrounding property or structures), on agricultural crops or other types of plants, or on the skin or fur of an animal.
• the term infestation is also intended to be synonymous with the term “infection” as that term is generally understood in the art, unless otherwise stated.
• alkyl used either alone or in compound words such as “haloalkyl” includes straight-chain or branched alkyls, such as methyl, ethyl, n -propyl, i -propyl, or the different butyl, pentyl or hexyl isomers.
• alkenyl includes straight-chain or branched alkenes such as ethenyl, 1-propenyl, 2-propenyl, and the different butenyl, pentenyl and hexenyl isomers.
• Alkenyl also includes polyenes such as 1,2-propadienyl and 2,4-hexadienyl.
• Alkynyl includes straight-chain or branched alkynes such as ethynyl, 1-propynyl, 2-propynyl and the different butynyl, pentynyl and hexynyl isomers. "Alkynyl” can also include moieties comprised of multiple triple bonds such as 2,5-hexadiynyl.
• Cycloalkyl includes, for example, cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
• cyclopropylmethyl denotes cyclopropyl substitution on a methyl moiety.
• halogen either alone or in compound words such as “haloalkyl”, or when used in descriptions such as “alkyl substituted with halogen” includes fluorine, chlorine, bromine or iodine. Further, when used in compound words such as “haloalkyl”, or when used in descriptions such as “alkyl substituted with halogen” said alkyl may be partially or fully substituted with halogen atoms which may be the same or different. Examples of “haloalkyl” or “alkyl substituted with halogen” include CF 3 , CH 2 Cl, CH 2 CF 3 and CCl 2 CF 3 .
• halocycloalkyl haloalkoxy
• haloalkenyl and the like, are defined analogously to the term “haloalkyl”.
• haloalkoxy include OCF 3 , OCH 2 CCl 3 , OCH 2 CH 2 CHF 2 and OCH 2 CF 3 .
• Alkylcarbonyl denotes a straight-chain or branched alkyl moiety bonded to a C(O) moiety.
• the chemical abbreviation C(O) as used herein represents a carbonyl moiety.
• alkylcarbonyl include C(O)CH 3 , C(O)CH 2 CH 2 CH 3 and C(O)CH(CH 3 ) 2 .
• C i -C j The total number of carbon atoms in a substituent group is indicated by the "C i -C j " prefix where i and j are numbers from 1 to 6.
• C 1 -C 3 alkyl designates methyl through propyl.
• ring member refers to an atom or other moiety (e.g., O or S(O) n ) forming the backbone of a ring.
• Q include
• Compounds of Formula 1 can exist as one or more stereoisomers.
• the various stereoisomers include enantiomers, diastereomers and atropisomers.
• one stereoisomer may be more active and/or may exhibit beneficial effects when enriched relative to the other stereoisomer(s) or when separated from the other stereoisomer(s). Additionally, the skilled artisan knows how to separate, enrich, and/or to selectively prepare said stereoisomers.
• the compounds Formula 1 may be present as a mixture of stereoisomers, individual stereoisomers or as an optically active form.
• Formula 1a two possible enantiomers of Formula 1 are depicted as Formula 1a and Formula 1b involving the isoxazoline chiral center identified with an asterisk (*). Analogously, other chiral centers are possible at, for example, R 1 , R 6 , R 9 and R 11 .
• Formula 1a has the ( S ) configuration at the chiral carbon
• Formula 1b has the (R) configuration at the chiral carbon.
• the method of this invention comprises racemic mixtures, for example, equal amounts of the enantiomers of Formulae 1a and 1b.
• the method of this invention includes compounds that are enriched compared to the racemic mixture in an enantiomer of Formula 1. Also included are the essentially pure enantiomers of compounds of Formula 1, for example, Formula 1a and Formula 1b.
• enantiomeric excess which is defined as (2x-1) ⁇ 100 %, where x is the mole fraction of the dominant enantiomer in the mixture (e.g., an ee of 20 % corresponds to a 60:40 ratio of enantiomers).
• compositions of Formula 1 have at least a 50 % enantiomeric excess; more preferably at least a 75 % enantiomeric excess; still more preferably at least a 90 % enantiomeric excess; and the most preferably at least a 94 % enantiomeric excess of the more active isomer.
• enantiomerically pure embodiments of the more active isomer are enantiomerically pure embodiments of the more active isomer.
• Compounds of Formula 1 can comprise additional chiral centers.
• the method of this invention comprises racemic mixtures as well as enriched and essentially pure stereoconfigurations at these additional chiral centers.
• Compounds of Formula 1 can exist as one or more conformational isomers due to restricted rotation about the amide bond in Formula 1.
• the method of this invention comprises mixtures of conformational isomers.
• the method of this invention includes compounds that are enriched in one conformer relative to others.
• Embodiments of the present invention as described in the Summary of the Invention include those described below.
• reference to "a compound of Formula 1" includes the definitions of substituents specified in the Summary of the Invention unless further defined in the Embodiments.
• Embodiments of this invention including Embodiments 1-72 above as well as any other embodiments described herein, can be combined in any manner.
• the compounds of Formula 1 or any of Embodiments 1-43 or Embodiments A-P can be used for the protection of an animal from an invertebrate parasitic pest by oral or parenteral administration of the compound.
• the invention is understood to include the compounds of Formula 1 or any of Embodiments 1-43 or Embodiments A-P (and compositions containing them) for use as an animal medicament, or more particularly a parasiticidal animal medicament.
• the animals to be protected are as defined in any of Embodiments 47-55.
• the invertebrate parasitic pests are as defined in any of Embodiments 56-68.
• the medicament may be in oral or parenteral dosage forms.
• the invention is also understood to include the use of compounds of Formula 1 or any of Embodiments 1-43 or Embodiments A-P in the manufacture of medicaments for the protection of an animal from a an invertebrate parasitic pest.
• the animals to be protected are as defined in any of Embodiments 47-55.
• the invertebrate parasitic pests are as defined in any of Embodiments 56-68.
• the medicament may be in oral or parenteral dosage forms.
• the invention is also understood to include compounds of Formula 1 or any of Embodiments 1-43 or Embodiments A-P for use in the manufacture of medicaments for the protection of an animal from an invertebrate parasitic pest.
• the animals to be protected are as defined in any of Embodiments 47-55.
• the invertebrate parasitic pests are as defined in any of Embodiments 56-68.
• the medicament may be in oral or parenteral dosage forms.
• the invention is also understood to include compounds of Formula 1 or any of Embodiments 1-43 or Embodiments A-P packaged and presented for the protection of an animal from an invertebrate parasitic pest.
• the animals to be protected are as defined in any of Embodiments 47-55.
• the invertebrate parasitic pests are as defined in any of Embodiments 56-68.
• the compounds of the invention may be packaged and presented as oral or parenteral dosage forms.
• the invention is also understood to include a process for manufacturing a composition for protecting an animal from an invertebrate parasitic pest characterized in that a compound of Claim 1 is admixed with at least one pharmaceutically or veterinarily acceptable carrier.
• the animals to be protected are as defined in any of Embodiments 47-55.
• the invertebrate parasitic pests are as defined in any of Embodiments 56-68.
• the compositions of the invention may be packaged and presented as oral or parenteral dosage forms.
• Isoxazolines of Formula 1 can be prepared as described in PCT Patent Publication WO 2005/085216 .
• N -oxides can form N -oxides; one skilled in the art will recognize those pyridine heterocycles which can form N -oxides.
• Synthetic methods for the preparation of N -oxides of pyridine heterocycles are very well known by one skilled in the art including the oxidation of heterocycles with peroxy acids such as peracetic and m -chloroperbenzoic acid (MCPBA), hydrogen peroxide, alkyl hydroperoxides such as t -butyl hydroperoxide, sodium perborate, and dioxiranes such as dimethyldioxirane.
• MCPBA peroxy acids
• alkyl hydroperoxides such as t -butyl hydroperoxide
• sodium perborate sodium perborate
• dioxiranes such as dimethyldioxirane
• salts of chemical compounds are in equilibrium with their corresponding nonsalt forms, salts share the biological utility of the nonsalt forms.
• the salts of the compounds of Formula 1 include acid-addition salts with inorganic or organic acids such as hydrobromic, hydrochloric, nitric, phosphoric, sulfuric, acetic, butyric, fumaric, lactic, maleic, malonic, oxalic, propionic, salicylic, tartaric, 4-toluenesulfonic or valeric acids.
• the method of the present invention comprises compounds selected from Formula 1, N -oxides and salts thereof.
• R 1 is Cl
• R 3 is Cl
• R 3 is Cl R 6 R 6 CH 2 CH 2 SMe CH 2 C(O)NH 2 CH 2 C(O)NH( c -Pr) CH 2 CH 2 SEt CH 2 C(O)NH(Me) CH 2 C(O)NH(CH 2 - c -Pr) CH 2 CH 2 S( n -Pr) CH 2 C(O)NH(Et) CH 2 C(O)NHCH 2 CH 2 Cl CH 2 CH 2 CH 2 CH 2 SMe CH 2 C(O)NH( n -Pr) CH 2 C(O)NHCH 2 CHF 2 CH 2 CH 2 CH 2 SEt CH 2 C(O)NH( i -Pr) CH 2 C(O)NHCH 2 CF 3 CH 2 CH 2 S(O)Me CH 2 C(O)NH( i -Bu) CH 2 C(O)NHCH 2 CH 2 CF 3 CH 2 CH 2 CH 2 S(O)Et CH 2 C(O)NH( s -Bu) CH 2 C(O)NH
• R 3 is Cl R 6 R 6 CH 2 CH 2 SMe CH 2 C(O)NH 2 CH 2 C(O)NH( c -Pr) CH 2 CH 2 SEt CH 2 C(O)NH(Me) CH 2 C(O)NH(CH 2 - c -Pr) CH 2 CH 2 S( n -Pr) CH 2 C(O)NH(Et) CH 2 C(O)NHCH 2 CH 2 Cl CH 2 CH 2 CH 2 CH 2 SMe CH 2 C(O)NH( n -Pr) CH 2 C(O)NHCH 2 CHF 2 CH 2 CH 2 CH 2 SEt CH 2 C(O)NH( i -Pr) CH 2 C(O)NHCH 2 CF 3 CH 2 CH 2 S(O)Me CH 2 C(O)NH( i -Bu) CH 2 C(O)NHCH 2 CH 2 CF 3 CH 2 CH 2 CH 2 S(O)Et CH 2 C(O)NH( s -Bu) CH 2 C(O)NH
• R 3 is Br R 6 R 6 CH 2 CH 2 SMe CH 2 C(O)NH 2 CH 2 C(O)NH( c -Pr) CH 2 CH 2 SEt CH 2 C(O)NH(Me) CH 2 C(O)NH(CH 2 - c -Pr) CH 2 CH 2 S( n -Pr) CH 2 C(O)NH(Et) CH 2 C(O)NHCH 2 CH 2 Cl CH 2 CH 2 CH 2 CH 2 SMe CH 2 C(O)NH( n -Pr) CH 2 C(O)NHCH 2 CHF 2 CH 2 CH 2 CH 2 SEt CH 2 C(O)NH( i -Pr) CH 2 C(O)NHCH 2 CF 3 CH 2 CH 2 S(O)Me CH 2 C(O)NH( i -Bu) CH 2 C(O)NHCH 2 CH 2 CF 3 CH 2 CH 2 CH 2 S(O)Et CH 2 C(O)NH( s -Bu) CH 2 C(O)NH
• compositions of Formula 1 compounds may also contain formulation auxiliaries and additives, known to those skilled in the art as formulation aids (some of which may be considered to also function as solid diluents, liquid diluents or surfactants).
• formulation auxiliaries and additives may control: pH (buffers), foaming during processing (antifoams such polyorganosiloxanes), sedimentation of active ingredients (suspending agents), viscosity (thixotropic thickeners), in-container microbial growth (antimicrobials), product freezing (antifreezes), color (dyes/pigment dispersions), wash-off (film formers or stickers), evaporation (evaporation retardants), and other formulation attributes.
• Film formers include, for example, polyvinyl acetates, polyvinyl acetate copolymers, polyvinylpyrrolidone-vinyl acetate copolymer, polyvinyl alcohols, polyvinyl alcohol copolymers and waxes.
• formulation auxiliaries and additives include those listed in McCutcheon's Volume 2: Functional Materials, annual International and North American editions published by McCutcheon's Division, The Manufacturing Confectioner Publishing Co. ; and PCT Publication WO 03/024222 .
• a composition comprising a compound of Formula 1 useful in the present method can further comprise a biologically effective amount of at least one additional parasitic invertebrate pest control active ingredient having a similar spectrum of control but a different site of action.
• the compounds of Formula 1 can be applied without other adjuvants, but most often application will be of a formulation comprising one or more active ingredients with suitable carriers, diluents, and surfactants and possibly in combination with a food depending on the contemplated end use.
• One method of application involves spraying a water dispersion or refined oil solution of a compound of Formula 1. Combinations with spray oils, spray oil concentrations, spreader stickers, adjuvants, other solvents, and synergists such as piperonyl butoxide often enhance compound efficacy.
• Such sprays can be applied from spray containers such as a can, a bottle or other container, either by means of a pump or by releasing it from a pressurized container, e.g., a pressurized aerosol spray can.
• Such spray compositions can take various forms, for example, sprays, mists, foams, fumes or fog.
• Such spray compositions thus can further comprise propellants, foaming agents, etc. as the case may be.
• a spray composition comprising a biologically effective amount of a compound or a composition of Formula 1 and a carrier.
• One embodiment of such a spray composition comprises a biologically effective amount of a compound or a composition of Formula 1 and a propellant.
• propellants include, but are not limited to, methane, ethane, propane, butane, isobutane, butene, pentane, isopentane, neopentane, pentene, hydrofluorocarbons, chlorofluorocarbons, dimethyl ether, and mixtures of the foregoing.
• a spray composition (and a method utilizing such a spray composition dispensed from a spray container) used to control at least one parasitic invertebrate pest selected from the group consisting of mosquitoes, black flies, stable flies, deer flies, horse flies, wasps, yellow jackets, hornets, ticks, spiders, ants, gnats, and the like, including individually or in combinations.
• the controlling of animal parasites includes controlling external parasites that are parasitic to the surface of the body of the host animal (e.g., shoulders, armpits, abdomen, inner part of the thighs) and internal parasites that are parasitic to the inside of the body of the host animal (e.g., stomach, intestine, lung, veins, under the skin, lymphatic tissue).
• External parasitic or disease transmitting pests include, for example, chiggers, ticks, lice, mosquitoes, flies, mites and fleas.
• Internal parasites include heartworms, hookworms and helminths.
• Compounds and compositions of Formula 1 are particularly suitable for combating external parasitic pests.
• Compounds and compositions of Formula 1 are suitable for systemic and/or non-systemic control of infestation or infection by parasites on animals.
• Compounds and compositions of Formula 1 are suitable for combating parasitic invertebrate pests that infest animal subjects including those in the wild, livestock and agricultural working animals.
• Livestock is the term used to refer (singularly or plurally) to a domesticated animal intentionally reared in an agricultural setting to make produce such as food or fiber, or for its labor; examples of livestock include cattle, sheep, goats, horses, pigs, donkeys, camels, buffalo, rabbits, hens, turkeys, ducks and geese (e.g., raised for meat, milk, butter, eggs, fur, leather, feathers and/or wool).
• fatalities and performance reduction in terms of meat, milk, wool, skins, eggs, etc.
• applying a composition comprising a compound of Formula 1 allows more economic and simple husbandry of animals.
• Compounds and compositions of Formula 1 are especially suitable for combating parasitic invertebrate pests that infest companion animals and pets (e.g., dogs, cats, pet birds and aquarium fish), research and experimental animals (e.g., hamsters, guinea pigs, rats and mice), as well as animals raised for/in zoos, wild habitats and/or circuses.
• companion animals and pets e.g., dogs, cats, pet birds and aquarium fish
• research and experimental animals e.g., hamsters, guinea pigs, rats and mice
• animals raised for/in zoos wild habitats and/or circuses.
• the animal is preferably a vertebrate, and more preferably a mammal, avian or fish.
• the animal subject is a mammal (including great apes, such as humans).
• Other mammalian subjects include primates (e.g., monkeys), bovine (e.g., cattle or dairy cows), porcine (e.g., hogs or pigs), ovine (e.g., goats or sheep), equine (e.g., horses), canine (e.g., dogs), feline (e.g., house cats), camels, deer, donkeys, buffalos, antelopes, rabbits, and rodents (e.g., guinea pigs, squirrels, rats, mice, gerbils, and hamsters).
• primates e.g., monkeys
• bovine e.g., cattle or dairy cows
• porcine e.g., hogs or pigs
• ovine
• Avians include Anatidae (swans, ducks and geese), Columbidae (e.g., doves and pigeons), Phasianidae (e.g., partridges, grouse and turkeys), Thesienidae (e.g., domestic chickens), Psittacines (e.g., parakeets, macaws, and parrots), game birds, and ratites (e.g., ostriches).
• Anatidae swans, ducks and geese
• Columbidae e.g., doves and pigeons
• Phasianidae e.g., partridges, grouse and turkeys
• Thesienidae e.g., domestic chickens
• Psittacines e.g., parakeets, macaws, and parrots
• game birds e.g.,
• Birds treated or protected by the compounds of Formula 1 can be associated with either commercial or noncommercial aviculture. These include Anatidae, such as swans, geese, and ducks, Columbidae, such as doves and domestic pigeons, Phasianidae, such as partridge, grouse and turkeys, Thesienidae, such as domestic chickens, and Psittacines, such as parakeets, macaws and parrots raised for the pet or collector market, among others.
• Anatidae such as swans, geese, and ducks
• Columbidae such as doves and domestic pigeons
• Phasianidae such as partridge, grouse and turkeys
• Thesienidae such as domestic chickens
• Psittacines such as parakeets, macaws and parrots raised for the pet or collector market, among others.
• fish shall be understood to include without limitation, the Teleosti grouping of fish, i.e., teleosts. Both the Salmoniformes order (which includes the Salmonidae family) and the Perciformes order (which includes the Centrarchidae family) are contained within the Teleosti grouping. Examples of potential fish recipients include the Salmonidae, Serranidae, Sparidae, Cichlidae, and Centrarchidae, among others.
• inventions are also contemplated to benefit from the inventive methods, including marsupials (such as kangaroos), reptiles (such as farmed turtles), and other economically important domestic animals for which the inventive methods are safe and effective in treating or preventing parasite infection or infestation.
• marsupials such as kangaroos
• reptiles such as farmed turtles
• other economically important domestic animals for which the inventive methods are safe and effective in treating or preventing parasite infection or infestation.
• Examples of parasitic invertebrate pests controlled by administering a pesticidally effective amount of a compound of Formula 1 to an animal to be protected include ectoparasites (arthropods, acarines, etc.) and endoparasites (helminths, e.g., nematodes, trematodes, cestodes, acanthocephalans, etc.).
• ectoparasites arthropods, acarines, etc.
• endoparasites e.g., nematodes, trematodes, cestodes, acanthocephalans, etc.
• helminthiasis The disease or group of diseases described generally as helminthiasis is due to infection of an animal host with parasitic worms known as helminths.
• helminths The term 'helminths' is meant to include nematodes, trematodes, cestodes and acanthocephalans.
• Helminthiasis is a prevalent and serious economic problem with domesticated animals such as swine, sheep, horses, cattle, goats, dogs, cats and poultry.
• Nematodes that are contemplated to be treated by the compounds of this invention and by the inventive methods include, without limitation, the following genera: Acanthocheilonema, Aelurostrongylus , Ancylostoma, Angiostrongylus, Ascaridia , Ascaris, Brugia, Bunostomum , Capillaria, Chabertia , Cooperia, Crenosoma , Dictyocaulus , Dioctophyme, Dipetalonema, Diphyllobothrium, Dirofilaria , Dracunculus , Enterobius , Filaroides, Haemonchus, Heterakis, Lagochilascaris, Loa, Mansonella, Muellerius, Necator, Nematodirus, Oesophagostomum, Ostertagia, Oxyuris
• the most common genera of nematodes infecting the animals referred to above are Haemonchus, Trichostrongylus , Ostertagia, Nematodirus, Cooperia, Ascaris, Bunostomum , Oesophagostomum, Chabertia, Trichuris , Strongylus , Trichonema , Dictyocaulus , Capillaria, Heterakis , Toxocara , Ascaridia , Oxyuris, Ancylostoma, Uncinaria, Toxascaris and Parascaris .
• Nematodirus such as Nematodirus, Cooperia and Oesophagostomum attack primarily the intestinal tract while others, such as Haemonchus and Ostertagia , are more prevalent in the stomach while others such as Dictyocaulus are found in the lungs.
• Still other parasites may be located in other tissues such as the heart and blood vessels, subcutaneous and lymphatic tissue and the like.
• Trematodes that are contemplated to be treated by the compounds of this invention and by the inventive methods include, without limitation, the following genera: Alaria , Fasciola, Nanophyetus, Opisthorchis, Paragonimus and Schistosoma.
• Cestodes that are contemplated to be treated by the compounds of this invention and by the inventive methods include, without limitation, the following genera: Diphyllobothrium , Diplydium , Spirometra and Taenia.
• the most common genera of parasites of the gastrointestinal tract of humans are Ancylostoma, Necator, Ascaris, Strongyloides, Trichinella, Capillaria, Trichuris and Enterobius .
• Other medically important genera of parasites which are found in the blood or other tissues and organs outside the gastrointestinal tract are the filarial worms such as Wuchereria , Brugia, Onchocerca and Loa, as well as Dracunculus and extra intestinal stages of the intestinal worms Strongyloides and Trichinella.
• helminth genera and species are known to the art, and are also contemplated to be treated by the compounds of Formula 1. These are enumerated in great detail in Textbook of Veterinary Clinical Parasitology, Volume 1, Helminths, E. J. L. Soulsby, F. A. Davis Co., Philadelphia, Pa .; Helminths, Arthropods and Protozoa, (6th Edition of Monnig's Veterinary Helminthology and Entomology), E. J. L. Soulsby, The Williams and Wilkins Co., Baltimore, Md .
• the compounds of Formula 1 are effective against a number of animal ectoparasites (e.g., arthropod ectoparasites of mammals and birds).
• animal ectoparasites e.g., arthropod ectoparasites of mammals and birds.
• Insect and acarine pests include, e.g., biting insects such as flies and mosquitoes, mites, ticks, lice, fleas, true bugs, parasitic maggots, and the like.
• Adult flies include, e.g., the horn fly or Haematobia irritans , the horse fly or Tabanus spp., the stable fly or Stomoxys calcitrans, the black fly or Simulium spp., the deer fly or Chrysops spp., the louse fly or Melophagus ovinus, and the tsetse fly or Glossina spp.
• Parasitic fly maggots include, e.g., the bot fly ( Oestrus ovis and Catterebra spp.), the blow fly or Phaenicia spp., the screwworm or Cochliomyia hominivorax , the cattle grub or Hypoderma spp., the fleeceworm and the Gastrophilus of horses.
• Mosquitoes include, for example, Culex spp., Anopheles spp. and Aedes spp.
• Mites include Mesostigmata spp. e.g., mesostigmatids such as the chicken mite, Dermanyssus gallinae; itch or scab mites such as Sarcoptidae spp. for example, Sarcoptes scabiei; mange mites such as Psoroptidae spp. including Chorioptes bovis and Psoroptes ovis; chiggers e.g., Trombiculidae spp. for example the North American chigger, Trombicula alfreddugesi .
• mesostigmatids such as the chicken mite, Dermanyssus gallinae
• itch or scab mites such as Sarcoptidae spp. for example, Sarcoptes scabiei
• mange mites such as Psoroptidae spp. including Chorioptes bovis and Psoroptes ovis
• Ticks include, e.g., soft-bodied ticks including Argasidae spp. for example Argas spp. and Ornithodoros spp.; hard-bodied ticks including Ixodidae spp., for example Rhipicephalus sanguineus, Dermacentor variabilis, Dermacentor andersoni, Amblyomma americanum, Ixodes scapularis and other Rhipicephalus spp. (including the former Boophilus genera).
• soft-bodied ticks including Argasidae spp. for example Argas spp. and Ornithodoros spp.
• hard-bodied ticks including Ixodidae spp., for example Rhipicephalus sanguineus, Dermacentor variabilis, Dermacentor andersoni, Amblyomma americanum, Ixodes scapularis and other Rhipicephalus spp. (including the former Boophilus genera).
• Lice include, e.g., sucking lice, e.g., Menopon spp. and Bovicola spp.; biting lice, e.g., Haematopinus spp., Linognathus spp. and Solenopotes spp.
• Fleas include, e.g., Ctenocephalides spp., such as dog flea ( Ctenocephalides canis ) and cat flea (Ctenocephalides felis ); Xenopsylla spp. such as oriental rat flea ( Xenopsylla cheopis ); and Pulex spp. such as human flea ( Patlex irritans ) .
• Ctenocephalides spp. such as dog flea ( Ctenocephalides canis ) and cat flea (Ctenocephalides felis ); Xenopsylla spp. such as oriental rat flea ( Xenopsylla cheopis ); and Pulex spp. such as human flea ( Patlex irritans ) .
• True bugs include, e.g., Cimicidae or e.g., the common bed bug (Cimex lectularius ); Triatominae spp. including triatomid bugs also known as kissing bugs; for example Rhodnius prolixus and Triatoma spp.
• flies, fleas, lice, mosquitoes, gnats, mites, ticks and helminths cause tremendous losses to the livestock and companion animal sectors.
• Arthropod parasites also are a nuisance to humans and can vector disease-causing organisms in humans and animals.
• the compounds of Formula 1 are especially effective against ectoparasites including Stomoxys calcitrans (stable fly); ticks such as Ixodes spp., Boophilus spp., Rhipicephalus spp., Amblyomma spp., Dermacentor spp., Hyalomma spp. and Haemaphysalis spp.; and fleas such as Ctenocephalides felis (cat flea) and Ctenocephalides canis (dog flea).
• Stomoxys calcitrans stable fly
• ticks such as Ixodes spp., Boophilus spp., Rhipicephalus spp., Amblyomma spp., Dermacentor spp., Hyalomma spp. and Haemaphysalis spp.
• fleas such as Ctenocephalides felis (cat flea) and Ctenocephalides canis (dog fle
• the compounds of Formula 1 may also be effective against ectoparasites including: flies such as Haematobia (Lyperosia) irritans (horn fly), Simulium spp. (blackfly), Glossina spp. (tsetse flies), Hydrotaea irritans (head fly), Musca autumnalis (face fly), Musca domestica (house fly), Morellia simplex (sweat fly), Tabanus spp. (horse fly), Hypoderma bovis, Hypoderma lineatum, Lucilia sericata, Lucilia cuprina (green blowfly), Calliphora spp.
• flies such as Haematobia (Lyperosia) irritans (horn fly), Simulium spp. (blackfly), Glossina spp. (tsetse flies), Hydrotaea irritans (head fly), Musca autumnalis (face fly), Musca domestic
• biologically active compounds or agents may be administered at the same or different times as the compounds of Formula 1. Such compounds, for example, may be useful adjuncts in Formula 1 compositions for the present method. As noted below, such biologically active compounds may be included in the composition of Formula 1.
• biologically active compounds for use in the present invention include the organophosphate pesticides. This class of pesticides has very broad activity as insecticides and, in certain instances, anthelminitic activity.
• Organophosphate pesticides include, e.g., dicrotophos, terbufos, dimethoate, diazinon, disulfoton, trichlorfon, azinphos-methyl, chlorpyrifos, malathion, oxydemeton-methyl, methamidophos, acephate, ethyl parathion, methyl parathion, mevinphos, phorate, carbofenthion and phosalone.
• compositions of Formula 1 compounds for the present method are also comtemplated to include carbamate-type pesticides, including, e.g., carbaryl, carbofuran, aldicarb, molinate, methomyl, carbofuran, etc., as well as combinations with the organochlorine type pesticides.
• Compositions of Formula 1 compounds are further contemplated to include combinations with biological pesticides, including repellents, the pyrethrins (as well as synthetic variations thereof, e.g., allethrin, resmethrin, permethrin, tralomethrin), and nicotine, that is often employed as an acaricide.
• miscellaneous pesticides including: Bacillus thuringiensis, chlorobenzilate, formamidines (e.g., amitraz), copper compounds (e.g., copper hydroxide and cupric oxychloride sulfate), cyfluthrin, cypermethrin, dicofol, endosulfan, esfenvalerate, fenvalerate, lambda-cyhalothrin, methoxychlor and sulfur.
• Bacillus thuringiensis chlorobenzilate
• formamidines e.g., amitraz
• copper compounds e.g., copper hydroxide and cupric oxychloride sulfate
• cyfluthrin e.g., cypermethrin, dicofol
• endosulfan esfenvalerate, fenvalerate, lambda-cyhalothrin, methoxychlor and
• anthelmintics such as, for example, avermectins (e.g., ivermectin, moxidectin, milbemycin), benzimidazoles (e.g., albendazole, triclabendazole), salicylanilides (e.g., closantel, oxyclozanide), substituted phenols (e.g., nitroxynil), pyrimidines (e.g., pyrantel), imidazothiazoles (e.g., levamisole) and praziquantel.
• avermectins e.g., ivermectin, moxidectin, milbemycin
• benzimidazoles e.g., albendazole, triclabendazole
• salicylanilides e.g., closantel, oxyclozanide
• substituted phenols e.g., nitroxynil
• Other biologically active compounds or agents useful in the Formula 1 compositions for the present method can be selected from Insect Growth Regulators (IGRs) and Juvenile Hormone Analogues (JHAs) such as diflubenzuron, triflumuron, fluazuron, cyromazine, methoprene, etc., thereby providing both initial and sustained control of parasites (at all stages of insect development, including eggs) on the animal subject, as well as within the environment of the animal subject.
• IGRs Insect Growth Regulators
• JHAs Juvenile Hormone Analogues
• biologically active compounds or agents useful in the Formula 1 compositions for the present method selected from the avermectin class of antiparasitic compounds.
• the avermectin family of compounds includes very potent antiparasitic agents known to be useful against a broad spectrum of endoparasites and ectoparasites in mammals.
• a preferred compound for use within the scope of the present invention is ivermectin.
• Ivermectin is a semi-synthetic derivative of avermectin and is generally produced as a mixture of at least 80% 22,23-dihydroavermectin B 1a and less than 20% 22,23-dihydroavermectin B 1b .
• Ivermectin is disclosed in U.S. Patent No. 4,199,569 .
• Abamectin is an avermectin that is disclosed as avermectin B 1a /B 1b in U.S. Patent No. 4,310,519 .
• Abamectin contains at least 80% of avermectin B 1a and not more than 20% of avermectin B 1b .
• doramectin also known as 25-cyclohexyl-avermectin B 1 .
• the structure and preparation of doramectin is disclosed in U.S. Patent No. 5,089,480 .
• Moxidectin also known as LL-F28249 alpha, is known from U.S. Patent No. 4,916,154 .
• avermectin is selamectin.
• Selamectin is 25-cyclohexyl-25-de(1-methylpropyl)-5-deoxy-22,23-dihydro-5-(hydroxyimino)-avermectin B 1 monosaccharide.
• Milbemycin or B41
• Milbemycin is a substance which is isolated from the fermentation broth of a milbemycin-producing strain of Streptomyces.
• the microorganism, the fermentation conditions and the isolation procedures are described in U.S. Patent Nos. 3,950,360 and 3,984,564 .
• Emamectin (4"-deoxy-4"-epi-methylaminoavermectin B 1 ), which can be prepared as described in U.S. Patent Nos. 5,288,710 and 5,399,717 , is a mixture of two homologues, 4"-deoxy-4"-epi-methylaminoavermectin B 1a and 4"-deoxy-4"-epi-methylaminoavermectin B 1b .
• a salt of emamectin is used.
• Non-limiting examples of salts of emamectin which may be used in the present invention include the salts described in U.S. Patent No.
• 5,288,710 e.g., salts derived from benzoic acid, substituted benzoic acid, benzenesulfonic acid, citric acid, phosphoric acid, tartaric acid, maleic acid, and the like.
• the emamectin salt used in the present invention is emamectin benzoate.
• Eprinomectin is chemically known as 4"-epi-acetylamino-4"-deoxy-avermectin B 1 .
• Eprinomectin was specifically developed to be used in all cattle classes and age groups. It was the first avermectin to show broad-spectrum activity against both endo- and ectoparasites while also leaving minimal residues in meat and milk. It has the additional advantage of being highly potent when delivered topically.
• compositions for the present method optionally comprise combinations of one or more of the following antiparasite compounds: imidazo[1,2-b]pyridazine compounds as described by U.S. Patent Application Publication No. 2005/0182059 A1 ; 1-(4-mono and di-halomethylsulphonylphenyl)-2-acylamino-3-fluoropropanol compounds, as described by U.S. Patent No. 7,361,689 ; trifluoromethanesulfonanilide oxime ether derivatives, as described by U.S. Patent No.
• the Formula 1 compositions may also further comprise a flukicide.
• Suitable flukicides include, for example, triclabendazole, fenbendazole, albendazole, clorsulon and oxibendazole. It will be appreciated that the above combinations may further include combinations of antibiotic, antiparasitic and anti-fluke active compounds.
• Formula 1 compositions as described herein for the present method, with other animal health remedies such as trace elements, anti-inflammatories, anti-infectives, hormones, dermatological preparations, including antiseptics and disinfectants, and immunobiologicals such as vaccines and antisera for the prevention of disease.
• animal health remedies such as trace elements, anti-inflammatories, anti-infectives, hormones, dermatological preparations, including antiseptics and disinfectants, and immunobiologicals such as vaccines and antisera for the prevention of disease.
• such antinfectives include one or more antibiotics that are optionally co-administered during treatment using the inventive methods, e.g., in a combined composition and/or in separate dosage forms.
• antibiotics suitable for this purpose include, for example, those listed herein below.
• florfenicol also known as D-(threo)-1-(4-methylsulfonylphenyl)-2-dichloroacetamido-3-fluoro-1-propanol.
• Another preferred antibiotic compound is D-(threo)-1-(4-methylsulfonylphenyl)-2-difluoroacetamido-3-fluoro-1-propanol.
• Another useful antibiotic is thiamphenicol. Processes for the manufacture of these antibiotic compounds, and intermediates useful in such processes, are described in U.S. Patent Nos.
• Tilmicosin is a macrolide antibiotic that is chemically defined as 20-dihydro-20-deoxy-20-( cis -3,5-dimethylpiperidin-1-yl)-desmycosin and is disclosed in U.S. Patent No. 4,820,695 .
• Tulathromycin may be prepared in accordance with the procedures set forth in U.S. Patent No. 6,825,327 .
• antibiotics for use in the present invention include the cephalosporins such as, for example, ceftiofur, cefquinome, etc.
• concentration of the cephalosporin in the formulation of the present invention optionally varies between about 1 mg/mL to 500 mg/mL.
• Another useful antibiotic includes the fluoroquinolones, such as, for example, enrofloxacin, danofloxacin, difloxacin, orbifloxacin and marbofloxacin.
• fluoroquinolones such as, for example, enrofloxacin, danofloxacin, difloxacin, orbifloxacin and marbofloxacin.
• enrofloxacin it may be administered in a concentration of about 100 mg/mL.
• Danofloxacin may be present in a concentration of about 180 mg/mL.
• Other useful macrolide antibiotics include compounds from the class of ketolides, or, more specifically, the azalides. Such compounds are described in, for example, U.S. Patent Nos. 6,514,945 ; 6,472,371 ; 6,270,768 ; 6,437,151 ; 6,271,255 ; 6,239,12 ; 5,958,888 ; 6,339,063 ; and 6,054,434 .
• antibiotics include the tetracyclines, particularly chlortetracycline and oxytetracycline.
• Other antibiotics may include ß-lactams such as penicillins, e.g., penicillin, ampicillin, amoxicillin, or a combination of amoxicillin with clavulanic acid or other beta lactamase inhibitors.
• Treatments of the invention are by conventional means such as by enteral administration in the form of, for example, tablets, capsules, drinks, drenching preparations, granulates, pastes, boli, feed-through procedures, or suppositories; or by parenteral administration, such as, for example, by injection (including intramuscular, subcutaneous, intravenous, intraperitoneal) or implants; or by nasal administration.
• enteral administration in the form of, for example, tablets, capsules, drinks, drenching preparations, granulates, pastes, boli, feed-through procedures, or suppositories
• parenteral administration such as, for example, by injection (including intramuscular, subcutaneous, intravenous, intraperitoneal) or implants; or by nasal administration.
• the compounds of Formula 1 may be administered in a controlled release form, for example in subcutaneous or orally adminstered slow release formulations.
• a parasiticidal composition comprises a mixture of a compound of Formula 1, an N -oxide or a salt thereof, with one or more pharmaceutically or veterinarily acceptable carriers comprising excipients and auxiliaries selected with regard to the intended route of administration (e.g., oral or parenteral administration such as injection) and in accordance with standard practice.
• a suitable carrier is selected on the basis of compatibility with the one or more active ingredients in the composition, including such considerations as stability relative to pH and moisture content. Therefore of note is a composition for protecting an animal from an invertebrate parasitic pest comprising a parasitically effective amount of a compound of Formula 1 and at least one carrier.
• a compound of Formula 1 can be formulated in suspension, solution or emulsion in oily or aqueous vehicles, and may contain adjuncts such as suspending, stabilizing and/or dispersing agents.
• the compounds of Formula 1 may also be formulated for bolus injection or continuous infusion.
• Pharmaceutical compositions for injection include aqueous solutions of water-soluble forms of active ingredients (e.g., a salt of an active compound), preferably in physiologically compatible buffers containing other excipients or auxiliaries as are known in the art of pharmaceutical formulation. Additionally, suspensions of the active compounds may be prepared in a lipophilic vehicle.
• Suitable lipophilic vehicles include fatty oils such as sesame oil, synthetic fatty acid esters such as ethyl oleate and triglycerides, or materials such as liposomes.
• Aqueous injection suspensions may contain substances that increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran.
• Formulations for injection may be presented in unit dosage form, e.g., in ampoules or in multi-dose containers.
• the active ingredient may be in powder form for constitution with a suitable vehicle, e.g., sterile, pyrogen-free water, before use.
• the compounds of Formula 1 may also be formulated as a depot preparation. Such long acting formulations may be administered by implantation (for example, subcutaneously or intramuscularly) or by intramuscular or subcutaneous injection.
• the compounds of Formula 1 may be formulated for this route of administration with suitable polymeric or hydrophobic materials (for instance, in an emulsion with a pharmacologically acceptable oil), with ion exchange resins, or as a sparingly soluble derivative such as, without limitation, a sparingly soluble salt.
• the compounds of Formula 1 can be delivered in the form of an aerosol spray using a pressurized pack or a nebulizer and a suitable propellant, e.g., without limitation, dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane or carbon dioxide.
• a suitable propellant e.g., without limitation, dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane or carbon dioxide.
• the dosage unit may be controlled by providing a valve to deliver a metered amount.
• Capsules and cartridges of, for example, gelatin for use in an inhaler or insufflator may be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.
• Compounds of Formula 1 have been discovered to have surprisingly favorable pharmacokinetic and pharmacodynamic properties providing systemic availability from oral administration and ingestion. Therefore after ingestion by the animal to be protected, parasiticidally effective concentrations of compounds of Formula 1 in the bloodstream protect the treated animal from blood-sucking pests such as fleas, ticks and lice. Therefore of note is a composition for protecting an animal from an invertebrate parasite pest in a form for oral administration (i.e. comprising, in addition to a parasiticidally effective amount of a compound of Formula 1, one or more carriers selected from binders and fillers suitable for oral administration and feed concentrate carriers).
• a compound of Formula 1 can be formulated with binders/fillers known in the art to be suitable for oral administration compositions, such as sugars and sugar derivatives (e.g., lactose, sucrose, mannitol, sorbitol), starch (e.g., maize starch, wheat starch, rice starch, potato starch), cellulose and derivatives (e.g., methylcellulose, carboxymethylcellulose, ethylhydroxycellulose), protein derivatives (e.g., zein, gelatin), and synthetic polymers (e.g., polyvinyl alcohol, polyvinylpyrrolidone).
• sugars and sugar derivatives e.g., lactose, sucrose, mannitol, sorbitol
• starch e.g., maize starch, wheat starch, rice starch, potato starch
• cellulose and derivatives e.g., methylcellulose, carboxymethylcellulose, ethylhydroxycellulose
• protein derivatives e
• lubricants e.g., magnesium stearate
• disintegrating agents e.g., cross-linked polyvinylpyrrolidinone, agar, alginic acid
• dyes or pigments can be added.
• Pastes and gels often also contain adhesives (e.g., acacia, alginic acid, bentonite, cellulose, xanthan gum, colloidal magnesium aluminum silicate) to aid in keeping the composition in contact with the oral cavity and not being easily ejected.
• a preferred embodiment is a composition of the present method formulated into a chewable and/or edible product (e.g., a chewable treat or edible tablet).
• a chewable and/or edible product e.g., a chewable treat or edible tablet.
• Such a product would ideally have a taste, texture and/or aroma favored by the animal to be protected so as to facilitate oral administration of the compound of Formula 1.
• the carrier is typically selected from high-performance feed, feed cereals or protein concentrates.
• feed concentrate-containing compositions can, in addition to the parasiticidal active ingredients, comprise additives promoting animal health or growth, improving quality of meat from animals for slaughter or otherwise useful to animal husbandry.
• additives can include, for example, vitamins, antibiotics, chemotherapeutics, bacteriostats, fungistats, coccidiostats and hormones.
• the compounds of Formula 1 may also be formulated in rectal compositions such as suppositories or retention enemas, using, e.g., conventional suppository bases such as cocoa butter or other glycerides.
• the formulations for the method of this invention may include an antioxidant, such as BHT (butylated hydroxytoluene).
• the antioxidant is generally present in amounts of at 0.1-5% (wt/vol).
• Some of the formulations require a solubilizer, such as oleic acid, to dissolve the active agent, particularly if spinosad is included.
• Common spreading agents used in these pour-on formulations include isopropyl myristate, isopropyl palmitate, caprylic/capric acid esters of saturated C 12 -C 18 fatty alcohols, oleic acid, oleyl ester, ethyl oleate, triglycerides, silicone oils and dipropylene glycol methyl ether.
• the pour-on formulations for the method of this invention are prepared according to known techniques. Where the pour-on is a solution, the parasiticide/insecticide is mixed with the carrier or vehicle, using heat and stirring if required. Auxiliary or additional ingredients can be added to the mixture of active agent and carrier, or they can be mixed with the active agent prior to the addition of the carrier. Pour-on formulations in the form of emulsions or suspensions are similarly prepared using known techniques.
• Liposomes and emulsions are well-known examples of delivery vehicles or carriers for hydrophobic drugs.
• organic solvents such as dimethylsulfoxide may be used, if needed.
• the rate of application required for effective parasitic invertebrate pest control (i.e. "pesticidally effective amount") will depend on such factors as the species of parasitic invertebrate pest to be controlled, the pest's life cycle, life stage, its size, location, time of year, host crop or animal, feeding behavior, mating behavior, ambient moisture, temperature, and the like.
• pesticidally effective amount necessary for the desired level of parasitic invertebrate pest control.
• a compound or composition of Formula 1 is administered in a pesticidally effective amount to an animal, particularly a homeothermic animal, to be protected from parasitic invertebrate pests.
• a pesticidally effective amount is the amount of active ingredient needed to achieve an observable effect diminishing the occurrence or activity of the target parasitic invertebrate pest.
• the pesticidally effective dose can vary for the various compounds and compositions useful for the method of the present invention, the desired pesticidal effect and duration, the target parasitic invertebrate pest species, the animal to be protected, the mode of application and the like, and the amount needed to achieve a particular result can be determined through simple experimentation.
• a dose of a compound of the present invention administered at suitable intervals typically ranges from about 0.01 mg/kg to about 100 mg/kg, and preferably from about 0.01 mg/kg to about 30 mg/kg of animal body weight.
• Suitable intervals for the administration of compounds of the present invention to animals range from about daily to about yearly. Of note are administration intervals ranging from about weekly to about once every 6 months. Of particular note are monthly adminstration intervals (i.e. administering the compound to the animal once every month).
• Control efficacy represents inhibition of parasitic invertebrate pest development (including mortality) that causes significantly reduced feeding.
• the pest control protection afforded by the compounds is not limited, however, to these species. See Index Tables A and B for compound descriptions.
• a1 g NMR data are in ppm downfield from tetramethylsilane. Couplings are designated by (s)-singlet, (d)-doublet, (t)-triplet, (q)-quartet, (dd)-doublet of doublets, (dt)-doublet of triplets, (br)-broad peaks, (m)-multiplet.
• a CD-1 ® mouse (about 30 g, male, obtained from Charles River Laboratories, Wilmington, MA) was orally dosed with a test compound in an amount of 10 mg/kg solubilized in propylene glycol/glycerol formal (60:40). Two hours after oral administration of the test compound, approximately 8 to 16 adult fleas were applied to each mouse. The fleas were then evaluated for mortality 48 hours after flea application to the mouse.
• a CD-1 ® mouse (about 30 g, male, obtained from Charles River Laboratories, Wilmington, MA) was orally dosed with a test compound in an amount of 10 mg/kg solubilized in propylene glycol/glycerol formal (60:40). Twenty four hours after oral administration of the test compound, approximately 8 to 16 adult fleas were applied to each mouse. The fleas were then evaluated for mortality 48 hours after flea application to the mouse.
• a CD-1 ® mouse (about 30 g, male, obtained from Charles River Laboratories, Wilmington, MA) was subcutaneously dosed with a test compound in an amount of 10 mg/kg solubilized in propylene glycol/glycerol formal (60:40). Two hours after oral administration of the test compound, approximately 8 to 16 adult fleas were applied to each mouse. The fleas were then evaluated for mortality 48 hours after flea application to the mouse.
• a test compound was solubilized in propylene glycol/glycerol formal (60:40) and then diluted in bovine blood to a final test rate of 30 ppm.
• the treated blood was placed in a tube, and the bottom of the tube was covered with a membrane. Approximately 10 adult cat fleas were allowed to feed through the membrane on the treated blood. The adult fleas were then evaluated for mortality 72 hours later.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Veterinary Medicine (AREA)
• General Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Public Health (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• Epidemiology (AREA)
• Dermatology (AREA)
• Nutrition Science (AREA)
• General Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Tropical Medicine & Parasitology (AREA)
• Physiology (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Agronomy & Crop Science (AREA)
• Plant Pathology (AREA)
• Dentistry (AREA)
• Wood Science & Technology (AREA)
• Zoology (AREA)
• Environmental Sciences (AREA)
• Pest Control & Pesticides (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Agricultural Chemicals And Associated Chemicals (AREA)
• Fodder In General (AREA)
• Feed For Specific Animals (AREA)
• Coloring Foods And Improving Nutritive Qualities (AREA)
• Micro-Organisms Or Cultivation Processes Thereof (AREA)
• Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
• Plural Heterocyclic Compounds (AREA)
• Medicinal Preparation (AREA)
• Nitrogen Condensed Heterocyclic Rings (AREA)

Priority Applications (4)

Applications Claiming Priority (2)

Related Parent Applications (1)

Related Child Applications (2)

Publications (2)

Family

ID=40003056

Family Applications (3)

Family Applications Before (2)

Country Status (22)

Cited By (1)

Families Citing this family (94)

Citations (40)

Family Cites Families (54)

• 2008
  • 2008-06-26 HU HUE15178198A patent/HUE037127T2/hu unknown
  • 2008-06-26 BR BRPI0810929A patent/BRPI0810929B8/pt active IP Right Grant
  • 2008-06-26 HR HRP20150978TT patent/HRP20150978T1/hr unknown
  • 2008-06-26 CA CA2971008A patent/CA2971008A1/fr not_active Abandoned
  • 2008-06-26 AU AU2008268321A patent/AU2008268321C1/en active Active
  • 2008-06-26 LT LTEP15178198.6T patent/LT2957284T/lt unknown
  • 2008-06-26 PT PT87719787T patent/PT2182945E/pt unknown
  • 2008-06-26 SI SI200831504T patent/SI2182945T1/sl unknown
  • 2008-06-26 KR KR1020167030535A patent/KR101769728B1/ko active Active
  • 2008-06-26 RU RU2010102529/15A patent/RU2508102C2/ru not_active IP Right Cessation
  • 2008-06-26 WO PCT/US2008/068268 patent/WO2009003075A1/fr not_active Ceased
  • 2008-06-26 CN CN201610078394.1A patent/CN105640952A/zh active Pending
  • 2008-06-26 MX MX2014010553A patent/MX368680B/es unknown
  • 2008-06-26 CN CN200880019716A patent/CN101743000A/zh active Pending
  • 2008-06-26 CA CA2685072A patent/CA2685072C/fr active Active
  • 2008-06-26 KR KR1020157020688A patent/KR101714291B1/ko active Active
  • 2008-06-26 DK DK15178198.6T patent/DK2957284T3/en active
  • 2008-06-26 SI SI200831932T patent/SI2957284T1/en unknown
  • 2008-06-26 EP EP08771978.7A patent/EP2182945B1/fr not_active Revoked
  • 2008-06-26 ES ES15178198.6T patent/ES2666187T3/es active Active
  • 2008-06-26 EP EP17206287.9A patent/EP3351243A1/fr active Pending
  • 2008-06-26 ES ES08771978.7T patent/ES2549731T3/es active Active
  • 2008-06-26 EP EP15178198.6A patent/EP2957284B1/fr not_active Revoked
  • 2008-06-26 MX MX2009013748A patent/MX2009013748A/es active IP Right Grant
  • 2008-06-26 DK DK08771978.7T patent/DK2182945T3/en active
  • 2008-06-26 PT PT151781986T patent/PT2957284T/pt unknown
  • 2008-06-26 KR KR1020107001744A patent/KR101714059B1/ko active Active
  • 2008-06-26 NO NO15178198A patent/NO2957284T3/no unknown
  • 2008-06-26 PL PL15178198T patent/PL2957284T3/pl unknown
  • 2008-06-26 MX MX2015011173A patent/MX361762B/es unknown
  • 2008-06-26 US US12/663,848 patent/US11278533B2/en active Active
  • 2008-06-26 JP JP2010515096A patent/JP6006471B2/ja active Active
• 2014
  • 2014-10-20 JP JP2014213472A patent/JP6099610B2/ja active Active
• 2016
  • 2016-06-22 JP JP2016123353A patent/JP6258410B2/ja active Active
  • 2016-07-12 US US15/207,999 patent/US20160317520A1/en not_active Abandoned
  • 2016-11-11 JP JP2016220118A patent/JP6167217B2/ja active Active
  • 2016-12-06 HK HK16113909.5A patent/HK1225622A1/zh unknown
• 2017
  • 2017-12-05 JP JP2017233023A patent/JP6411621B2/ja active Active
• 2018
  • 2018-03-16 HR HRP20180453TT patent/HRP20180453T1/hr unknown
  • 2018-03-19 CY CY20181100313T patent/CY1120038T1/el unknown
  • 2018-08-07 HK HK18110143.5A patent/HK1250648A1/en unknown
  • 2018-08-14 US US16/103,836 patent/US20180353494A1/en not_active Abandoned
  • 2018-09-25 JP JP2018178283A patent/JP2019014728A/ja active Pending

Patent Citations (43)

Non-Patent Citations (10)

Also Published As

Similar Documents

Legal Events